Jacob F. Wood
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jacob F. Wood has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Madhu Vishnu Sankar Reddy Rami Reddy
Department of Neurosurgery, Department of Surgery, The University of Toledo College of Medicine and Life Sciences, Toledo, USA
4 shared publications - Robert Erne McCullumsmith
Chair of Department of Neurosciences and Psychiatry The University of Toledo 3000 Arlington Avenue 43615 Toledo OH
4 shared publications - Ali Sajid Imami
Department of Neurosciences and Psychiatry, The University of Toledo College of Medicine, Toledo, OH 43614, USA
2 shared publications Jacob J. Tan
Department of Neurosciences and Psychiatry University of Toledo College of Medicine Toledo Ohio USA
2 shared publications- Shawn C. Murphy
Department of Neurosciences and Psychiatry, The University of Toledo College of Medicine and Life Sciences, Toledo, USA
2 shared publications - Tarak Davuluri
Department of Neurosciences and Psychiatry, The University of Toledo College of Medicine and Life Sciences, Toledo, USA
2 shared publications
Latest Publications
- Open Access
- 5 November 2026
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 37 (1) , 6
Patient-reported outcomes, predictive modeling, and artificial intelligence in spine surgery: current limitations and future directions
Introduction: Chronic back pain is a leading cause of disability worldwide, contributing to reduced productivity and diminished quality of life for many patients. Spine surgery, particularly lumbar decompression and fusion, serves as an intensive intervention after conservative measures fail. Despite advances in surgical technique and instrumentation, outcomes remain highly variable, with up to half of patients experiencing little or no meaningful improvement. This variability has prompted growing interest in predictive models that forecast which patients are most likely to benefit from surgery. Methods: This review examines the current landscape of predictive modeling for patient-reported outcomes (PROs) in spine surgery. We evaluated the use of PRO instruments, which have become central to assessing surgical success. We further explored existing predictive models that incorporate demographic, clinical, and psychosocial variables, as well as emerging applications of artificial intelligence (AI) and machine-learning techniques aimed at improving diagnostic accuracy and prognostic performance. Results: Current predictive models demonstrate variable performance across populations and remain constrained by incomplete datasets, inconsistencies in definitions, and limited integration of psychosocial factors. While most models report moderate discrimination for categorical outcomes (AUC 0.62–0.84), the subjective nature of PROs and the complexity of postoperative recovery pose challenges to accurate prediction. Machine-learning approaches, including neural networks, show promise in identifying complex relationships among diverse predictors of surgical outcomes. Future advancements will rely on leveraging multimodal data sources and integrating them through AI-driven frameworks. Transparency and external validation remain essential for clinical implementation. Conclusion: While PROs remain essential for understanding patient experiences and benchmarking surgical success, they often fall short as standalone predictive tools. The next generation of modeling should integrate multidimensional data and utilize AI’s capacity to detect clinically meaningful patterns. When implemented, these models have the potential to enhance preoperative counseling, guide surgical decision-making, and advance personalized spine care.
- 5 November 2026
- Published by Springer Nature in European Journal of Orthopaedic Surgery & Traumatology
- Vol. 37 (1) , 6
Open AccessPatient-reported outcomes, predictive modeling, and artificial intelligence in spine surgery: current limitations and future directions
Introduction: Chronic back pain is a leading cause of disability worldwide, contributing to reduced productivity and diminished quality of life for many patients. Spine surgery, particularly lumbar decompression and fusion, serves as an intensive intervention after conservative measures fail. Despite advances in surgical technique and instrumentation, outcomes remain highly variable, with up to half of patients experiencing little or no meaningful improvement. This variability has prompted growing interest in predictive models that forecast which patients are most likely to benefit from surgery. Methods: This review examines the current landscape of predictive modeling for patient-reported outcomes (PROs) in spine surgery. We evaluated the use of PRO instruments, which have become central to assessing surgical success. We further explored existing predictive models that incorporate demographic, clinical, and psychosocial variables, as well as emerging applications of artificial intelligence (AI) and machine-learning techniques aimed at improving diagnostic accuracy and prognostic performance. Results: Current predictive models demonstrate variable performance across populations and remain constrained by incomplete datasets, inconsistencies in definitions, and limited integration of psychosocial factors. While most models report moderate discrimination for categorical outcomes (AUC 0.62–0.84), the subjective nature of PROs and the complexity of postoperative recovery pose challenges to accurate prediction. Machine-learning approaches, including neural networks, show promise in identifying complex relationships among diverse predictors of surgical outcomes. Future advancements will rely on leveraging multimodal data sources and integrating them through AI-driven frameworks. Transparency and external validation remain essential for clinical implementation. Conclusion: While PROs remain essential for understanding patient experiences and benchmarking surgical success, they often fall short as standalone predictive tools. The next generation of modeling should integrate multidimensional data and utilize AI’s capacity to detect clinically meaningful patterns. When implemented, these models have the potential to enhance preoperative counseling, guide surgical decision-making, and advance personalized spine care.
- Open Access
- 2 June 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70625
Real‐World Clinical Datasets in Practice: Applications for Learners, Clinician‐Educators, and Health Services Teams
Real‐world clinical databases offer students, residents, fellows, clinician‐educators, librarians, and early‐career investigators an accessible entry point into population health, quality improvement, and outcomes research. Leveraging large‐scale, de‐identified datasets enables the investigation of healthcare delivery, cost, treatment effectiveness, and clinical outcomes without the need for patient recruitment or extensive funding sources. This review provides a synopsis of four widely used real‐world clinical datasets: the Healthcare Cost and Utilization Project (HCUP, low‐cost with a Data Use Agreement), the Medical Information Mart for Intensive Care (MIMIC‐IV, openly available), TriNetX (subscription‐based), and Epic Cosmos (institutional access). Highlighting their structure, data types, access requirements, and ideal use cases, the distinguishing features of each database are discussed. Finally, we provide guidance on how learners and research teams can formulate research questions, identify the appropriate dataset, and leverage mentorship resources for database‐focused research, allowing them to meaningfully engage in data‐driven research and contribute to improving healthcare delivery and patient outcomes.
- 2 June 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (6) , e70625
Open AccessReal‐World Clinical Datasets in Practice: Applications for Learners, Clinician‐Educators, and Health Services Teams
Real‐world clinical databases offer students, residents, fellows, clinician‐educators, librarians, and early‐career investigators an accessible entry point into population health, quality improvement, and outcomes research. Leveraging large‐scale, de‐identified datasets enables the investigation of healthcare delivery, cost, treatment effectiveness, and clinical outcomes without the need for patient recruitment or extensive funding sources. This review provides a synopsis of four widely used real‐world clinical datasets: the Healthcare Cost and Utilization Project (HCUP, low‐cost with a Data Use Agreement), the Medical Information Mart for Intensive Care (MIMIC‐IV, openly available), TriNetX (subscription‐based), and Epic Cosmos (institutional access). Highlighting their structure, data types, access requirements, and ideal use cases, the distinguishing features of each database are discussed. Finally, we provide guidance on how learners and research teams can formulate research questions, identify the appropriate dataset, and leverage mentorship resources for database‐focused research, allowing them to meaningfully engage in data‐driven research and contribute to improving healthcare delivery and patient outcomes.
- 31 March 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 257, 116963
The impact of tumor location in pancreatic cancer: Survival outcomes after resection in a multi-institutional TriNetX analysis
- 31 March 2026
- Published by Elsevier in The American Journal of Surgery
- Vol. 257, 116963
The impact of tumor location in pancreatic cancer: Survival outcomes after resection in a multi-institutional TriNetX analysis
- Open Access
- 17 February 2026
- Published by University of Toledo in Translation: The University of Toledo Journal of Medical Sciences
- Vol. 15 (S1)
Ventriculoperitoneal Shunt-Associated Neuropsychiatric Symptoms: A Literature Review and Two Case Reports
Ventriculoperitoneal (VP) shunts are a common use for the treatment of hydrocephalus, which is a condition causing excessive cerebrospinal fluid (CSF) buildup in the brain. The shunt drains the CSF from the brain and into the abdomen, where it can be absorbed by the body. Although a widely used and successful procedure, it is unclear whether neurosurgical placement of this shunt may directly cause psychiatric abnormalities, especially regarding the dopaminergic system. In this paper, we first review relevant literature and discuss the dopamine circuitry in the brain. The literature suggests a shunt-associated clinical syndrome, which may include a reduction in facial and/or verbal expressivity, reduced willful movement, rigidity, and vertical gaze palsy. Typical presentation occurs within three months of a shunt revision. In patients with a VP shunt, these signs may be a strong indicator of mechanical or functional shunt malfunction. We then present two cases of hydrocephalus managed with a VP shunt, where both patients developed symptoms suggestive of psychosis and/or dopamine pathway pathology after shunt placement. We conclude that clinicians should have a suspicion for shunt-associated symptomology in patients with a history of recently treated hydrocephalus who present with psychomotor, personality, or cognitive changes.
- 17 February 2026
- Published by University of Toledo in Translation: The University of Toledo Journal of Medical Sciences
- Vol. 15 (S1)
Open AccessVentriculoperitoneal Shunt-Associated Neuropsychiatric Symptoms: A Literature Review and Two Case Reports
Ventriculoperitoneal (VP) shunts are a common use for the treatment of hydrocephalus, which is a condition causing excessive cerebrospinal fluid (CSF) buildup in the brain. The shunt drains the CSF from the brain and into the abdomen, where it can be absorbed by the body. Although a widely used and successful procedure, it is unclear whether neurosurgical placement of this shunt may directly cause psychiatric abnormalities, especially regarding the dopaminergic system. In this paper, we first review relevant literature and discuss the dopamine circuitry in the brain. The literature suggests a shunt-associated clinical syndrome, which may include a reduction in facial and/or verbal expressivity, reduced willful movement, rigidity, and vertical gaze palsy. Typical presentation occurs within three months of a shunt revision. In patients with a VP shunt, these signs may be a strong indicator of mechanical or functional shunt malfunction. We then present two cases of hydrocephalus managed with a VP shunt, where both patients developed symptoms suggestive of psychosis and/or dopamine pathway pathology after shunt placement. We conclude that clinicians should have a suspicion for shunt-associated symptomology in patients with a history of recently treated hydrocephalus who present with psychomotor, personality, or cognitive changes.
- Open Access
- 17 February 2026
- Published by University of Toledo in Translation: The University of Toledo Journal of Medical Sciences
- Vol. 15 (S1)
Impact of Wait Times on Psychiatric Outcomes: A Mini-Review
Prolonged wait times in psychiatric care (in the emergency department, outpatient setting, or between diagnosis and treatment initiation) have been associated with worsening clinical outcomes. This mini-review explores how wait times in psychiatric care contribute to worsening symptoms and emphasizes the need for earlier intervention. Psychiatric patients admitted through the emergency department stayed in the emergency department 3.2 times longer compared to nonpsychiatric admission. Following in-patient psychiatric care, patients are typically referred to outpatient visits. From 2011 to 2022 an increase in the median waiting time for outpatient psychiatic visits from 15 to 50 days was reported. After outpatient visits, patients still experience delays in their treatment initiation. Longer intervals between diagnosis and treatment initiation have been associated with worsening clinical outcomes. All these delays in psychiatric care highlight critical periods where early intervention can improve symptom progression and clinical outcomes.
- 17 February 2026
- Published by University of Toledo in Translation: The University of Toledo Journal of Medical Sciences
- Vol. 15 (S1)
Open AccessImpact of Wait Times on Psychiatric Outcomes: A Mini-Review
Prolonged wait times in psychiatric care (in the emergency department, outpatient setting, or between diagnosis and treatment initiation) have been associated with worsening clinical outcomes. This mini-review explores how wait times in psychiatric care contribute to worsening symptoms and emphasizes the need for earlier intervention. Psychiatric patients admitted through the emergency department stayed in the emergency department 3.2 times longer compared to nonpsychiatric admission. Following in-patient psychiatric care, patients are typically referred to outpatient visits. From 2011 to 2022 an increase in the median waiting time for outpatient psychiatic visits from 15 to 50 days was reported. After outpatient visits, patients still experience delays in their treatment initiation. Longer intervals between diagnosis and treatment initiation have been associated with worsening clinical outcomes. All these delays in psychiatric care highlight critical periods where early intervention can improve symptom progression and clinical outcomes.
- Open Access
Integrative Transcriptomic and Perturbagen Analyses Reveal Sex-Specific Molecular Signatures Across Glioma Subtypes
Background: Emerging evidence suggests that biological sex shapes glioma biology and therapeutic response. Methods: We performed a sex-stratified analysis of CGGA (Chinese Glioma Genome Atlas) RNA sequencing data comparing low-grade glioma (LGG) with high-grade glioma (HGG) and glioblastoma (GBM). Using the 3PodR framework, we integrated differential expression analysis with Gene Set Enrichment Analysis (GSEA), EnrichR, leading-edge analysis, and iLINCS drug repurposing. Results: These comparisons provide a proxy for biological processes underlying malignant transformation. In LGG vs. HGG, 973 significantly differentially expressed genes (DEGs) were identified in females and 1236 in males, with 15.5% and 33.5% unique to each sex, respectively. In LGG vs. GBM, 2011 DEGs were identified in females and 2537 in males, with 12.6% and 30.7% being unique. Gene-level contrasts included GLI1 upregulation in males and downregulation in females, GCGR upregulation in males, MYOD1 upregulation in females, and HIST1H2BH downregulation in males. Additional top DEGs included PRLHR, DGKK, DNMBP-AS1, HOXA9, CTB-1I21.1, RP11-47I22.1, HPSE2, SAA1, DLK1, H19, PLA2G2A, and PI3. In both sexes, LGG–HGG and LGG–GBM grade comparisons converged on neuronal and synaptic programs, with enrichment of glutamatergic receptor genes and postsynaptic modules, including GRIN2B, GRIN2A, GRIN2C, GRIN1, and CHRNA7. In contrast, collateral pathways diverged by sex: females showed downregulation of mitotic and chromosome-segregation programs, whereas males showed reduction of extracellular matrix and immune-interaction pathways. Perturbagen analysis nominated signature-reversing compounds across sexes, including histone deacetylase inhibitors, Aurora kinase inhibitors, microtubule-targeting agents such as vindesine, and multi-kinase inhibitors targeting VEGFR, PDGFR, FLT3, PI3K, and MTOR. Conclusions: Glioma grade comparisons reveal a shared neuronal–synaptic program accompanied by sex-specific transcriptional remodeling. These findings support sex-aware therapeutic strategies that pair modulation of neuron–glioma coupling with chromatin- or receptor tyrosine kinase/angiogenic-targeted agents, and they nominate biomarkers such as GLI1, MYOD1, GCGR, PRLHR, and HIST1H2BH for near-term validation.
Open AccessIntegrative Transcriptomic and Perturbagen Analyses Reveal Sex-Specific Molecular Signatures Across Glioma Subtypes
Background: Emerging evidence suggests that biological sex shapes glioma biology and therapeutic response. Methods: We performed a sex-stratified analysis of CGGA (Chinese Glioma Genome Atlas) RNA sequencing data comparing low-grade glioma (LGG) with high-grade glioma (HGG) and glioblastoma (GBM). Using the 3PodR framework, we integrated differential expression analysis with Gene Set Enrichment Analysis (GSEA), EnrichR, leading-edge analysis, and iLINCS drug repurposing. Results: These comparisons provide a proxy for biological processes underlying malignant transformation. In LGG vs. HGG, 973 significantly differentially expressed genes (DEGs) were identified in females and 1236 in males, with 15.5% and 33.5% unique to each sex, respectively. In LGG vs. GBM, 2011 DEGs were identified in females and 2537 in males, with 12.6% and 30.7% being unique. Gene-level contrasts included GLI1 upregulation in males and downregulation in females, GCGR upregulation in males, MYOD1 upregulation in females, and HIST1H2BH downregulation in males. Additional top DEGs included PRLHR, DGKK, DNMBP-AS1, HOXA9, CTB-1I21.1, RP11-47I22.1, HPSE2, SAA1, DLK1, H19, PLA2G2A, and PI3. In both sexes, LGG–HGG and LGG–GBM grade comparisons converged on neuronal and synaptic programs, with enrichment of glutamatergic receptor genes and postsynaptic modules, including GRIN2B, GRIN2A, GRIN2C, GRIN1, and CHRNA7. In contrast, collateral pathways diverged by sex: females showed downregulation of mitotic and chromosome-segregation programs, whereas males showed reduction of extracellular matrix and immune-interaction pathways. Perturbagen analysis nominated signature-reversing compounds across sexes, including histone deacetylase inhibitors, Aurora kinase inhibitors, microtubule-targeting agents such as vindesine, and multi-kinase inhibitors targeting VEGFR, PDGFR, FLT3, PI3K, and MTOR. Conclusions: Glioma grade comparisons reveal a shared neuronal–synaptic program accompanied by sex-specific transcriptional remodeling. These findings support sex-aware therapeutic strategies that pair modulation of neuron–glioma coupling with chromatin- or receptor tyrosine kinase/angiogenic-targeted agents, and they nominate biomarkers such as GLI1, MYOD1, GCGR, PRLHR, and HIST1H2BH for near-term validation.
- Open Access
- 10 December 2025
- Published by University of Toledo in Translation: The University of Toledo Journal of Medical Sciences
- Vol. 14 (S4)
Drug Identification and Repurposing in Lung Adenocarcinoma: Differences in Male and Female Subjects
Lung adenocarcinoma (LACA) presents with a range of debilitating symptoms, including chronic cough, hemoptysis, and shortness of breath. In this study, we reanalyzed a published transcriptomic dataset to compare male and female LACA samples with healthy lung tissue and identify potential therapeutic targets capable of reversing disease-associated gene expression signatures. Utilizing cutting-edge bioinformatics approaches, including differential expression analysis, pathway analyses and analyses of signature-reversing drug profiles, we assessed male and female signatures separately. Using Gene Set Enrichment Analysis, we identified sex-specific differences in tumor-associated pathways, including the downregulation of blood angiogenesis in female lung adenocarcinoma subjects. Leading-edge gene analysis further revealed that angiogenesis-related genes were downregulated in both sexes, though the specific genes contributing to these pathways differed between males and females. Integrative drug repurposing analysis using the LINCs database, based on our transcriptomic profiles, uncovered potential therapeutic candidates for male and female LACA compared with healthy controls. Notably, a VEGFR inhibitor showed the highest discordance score in males, while a CLK2 inhibitor demonstrated one of the highest discordance scores in females. Together, these findings highlight distinct molecular and pharmacologic signatures between sexes and suggest potential sex-specific therapeutic strategies for lung adenocarcinoma.
- 10 December 2025
- Published by University of Toledo in Translation: The University of Toledo Journal of Medical Sciences
- Vol. 14 (S4)
Open AccessDrug Identification and Repurposing in Lung Adenocarcinoma: Differences in Male and Female Subjects
Lung adenocarcinoma (LACA) presents with a range of debilitating symptoms, including chronic cough, hemoptysis, and shortness of breath. In this study, we reanalyzed a published transcriptomic dataset to compare male and female LACA samples with healthy lung tissue and identify potential therapeutic targets capable of reversing disease-associated gene expression signatures. Utilizing cutting-edge bioinformatics approaches, including differential expression analysis, pathway analyses and analyses of signature-reversing drug profiles, we assessed male and female signatures separately. Using Gene Set Enrichment Analysis, we identified sex-specific differences in tumor-associated pathways, including the downregulation of blood angiogenesis in female lung adenocarcinoma subjects. Leading-edge gene analysis further revealed that angiogenesis-related genes were downregulated in both sexes, though the specific genes contributing to these pathways differed between males and females. Integrative drug repurposing analysis using the LINCs database, based on our transcriptomic profiles, uncovered potential therapeutic candidates for male and female LACA compared with healthy controls. Notably, a VEGFR inhibitor showed the highest discordance score in males, while a CLK2 inhibitor demonstrated one of the highest discordance scores in females. Together, these findings highlight distinct molecular and pharmacologic signatures between sexes and suggest potential sex-specific therapeutic strategies for lung adenocarcinoma.
- Open Access
- 22 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7041
Identification of Drug Repurposing Candidates for Coxsackievirus B3 Infection in iPSC-Derived Brain-like Endothelial Cells
The enterovirus Coxsackievirus B3 causes a range of serious health problems, including aseptic meningitis, myocarditis, and pancreatitis. Currently, Coxsackievirus B3 has no targeted antiviral treatments or vaccines, leaving supportive care as the primary management option. Understanding how Coxsackievirus B3 interacts with and alters the blood–brain barrier may help identify new therapies to combat this often-devastating infection. We reanalyzed a previously published RNA sequencing dataset for Coxsackievirus B3-infected human-induced pluripotent stem-cell-derived brain endothelial cells (iBECs) to examine how Coxsackievirus B3 altered mRNA expression. By integrating GSEA, EnrichR, and iLINCs-based perturbagen analysis, we present a novel, systems-level approach to uncover potential drug repurposing candidates for CVB3 infection. We found dynamic changes in host transcriptomic response to Coxsackievirus B3 infection at 2- and 5-day infection time points. Downregulated pathways included ribosomal biogenesis and protein synthesis, while upregulated pathways included a defense response to viruses, and interferon production. Using iLINCs transcriptomic analysis, MEK, PDGFR, and VEGF inhibitors were identified as possible novel antiviral therapeutics. Our findings further elucidate Coxsackievirus B3-associated pathways in (iBECs) and highlight potential drug repurposing candidates, including pelitinib and neratinib, which may disrupt Coxsackievirus B3 pathology at the blood–brain barrier (BBB).
- 22 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7041
Open AccessIdentification of Drug Repurposing Candidates for Coxsackievirus B3 Infection in iPSC-Derived Brain-like Endothelial Cells
The enterovirus Coxsackievirus B3 causes a range of serious health problems, including aseptic meningitis, myocarditis, and pancreatitis. Currently, Coxsackievirus B3 has no targeted antiviral treatments or vaccines, leaving supportive care as the primary management option. Understanding how Coxsackievirus B3 interacts with and alters the blood–brain barrier may help identify new therapies to combat this often-devastating infection. We reanalyzed a previously published RNA sequencing dataset for Coxsackievirus B3-infected human-induced pluripotent stem-cell-derived brain endothelial cells (iBECs) to examine how Coxsackievirus B3 altered mRNA expression. By integrating GSEA, EnrichR, and iLINCs-based perturbagen analysis, we present a novel, systems-level approach to uncover potential drug repurposing candidates for CVB3 infection. We found dynamic changes in host transcriptomic response to Coxsackievirus B3 infection at 2- and 5-day infection time points. Downregulated pathways included ribosomal biogenesis and protein synthesis, while upregulated pathways included a defense response to viruses, and interferon production. Using iLINCs transcriptomic analysis, MEK, PDGFR, and VEGF inhibitors were identified as possible novel antiviral therapeutics. Our findings further elucidate Coxsackievirus B3-associated pathways in (iBECs) and highlight potential drug repurposing candidates, including pelitinib and neratinib, which may disrupt Coxsackievirus B3 pathology at the blood–brain barrier (BBB).